Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 18, 2011

View Archived Issues

ONO-2952 emerges as a potential treatment for stress-related disorders

Anti-alpha-V/beta-6 antibody inhibits liver fibrosis

Sunshine Biopharma completes preclinical studies of Adva-27a

Roche and Aileron Therapeutics expand stapled peptide drug partnership

Studies point to new treatments for osteogenesis imperfecta / News in Context

EZN-3042 administered with docetaxel in phase I study

Promising preclinical results presented for LDK-378

Protein linked to prognosis of adenocarcinomas of the lung

New agents for tuberculosis disclosed by Chinese team

Novel lysophospholipid S1P1 receptor agonists prepared by GSK

Daiichi Sankyo patents novel erythropoietin production enhancers

New hydromorphone prodrugs disclosed by PharmacoFore

PharmacoFore synthesizes novel ketone-modified opioids

Arcarios receives grant for development of drugs that promote bone growth

European Commission approves Pfizer's Vyndaqel for TTR-FAP

Influenza vaccine inhibits multiple H5N1 strains in phase I trial

Takeda updates Dexilant product label

Full enrolment reached in Biothera's phase II Imprime PGG trial in NSCLC

Eli Lilly provides additional funds to Infectious Disease Research Institute for new TB therapies

FDA supports proposed clinical trial design for Xifaxan in IBS

FDA grants priority review to Northera NDA

Emergent BioSolutions begins study of BioThrax for postexposure to anthrax

Nile Therapeutics' phase I trial of subcutaneous cenderitide meets primary endpoint

Bionovo randomizes first patient in phase III trial of Menerba

EMA accepts Nuedexta MAA for filing

FDA approves Jakafi for patients with myelofibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...